Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.In the MK-8591A-052 trial, the suppression was on bictegravir/emtricitabine/tenofovir alafenamidei (BIC/FTC/TAF) and baseline antiretroviral therapy (bART) in tri ...